Michal N.
- Country
- Poland
- Department
- 2208; Santa Familia PTG Lodz
Research Overview
- A Randomized, Double-masked Study Comparing the Efficacy and Safety of AVT29 Versus High-Dose Aflibercept in Participants with Diabetic Macular Edema
- Phase 3 Trial Comparing Efficacy, Safety, and Immunogenicity of Aflibercept (RBS-001) Versus Aflibercept in Neovascular Age-Related Macular Degeneration
- Evaluation of Intravitreal OPT-302 and Aflibercept Versus Aflibercept Monotherapy in Neovascular Age-related Macular Degeneration Patients
Data & Insights
Has run more than one trial at 44 of 128 partner sites.
Specializations
Ophthalmic Disorders
The investigator specializes in treating complex neovascular age-related macular degeneration (wet AMD), focusing on innovative therapeutic approaches for managing retinal conditions.
- Advanced retinal disease management
- Combination therapy approaches
- Intravitreal treatment administration
Research interests include evaluating novel therapeutic agents for treating retinal disorders affecting elderly populations.
Thyroid Eye Disease
Demonstrates extensive expertise in the treatment of thyroid eye disease (TED), with particular focus on investigating both intravenous and subcutaneous therapeutic interventions.
- Proptosis reduction strategies
- Novel biological therapies
- Long-term disease management
Explores various treatment administration routes and dosing schedules to optimize therapeutic outcomes for TED patients.
Therapeutic Innovation
Focuses on evaluating emerging biological treatments and their application in ophthalmologic conditions, particularly in autoimmune-related eye disorders.
- Safety and tolerability assessment
- Dose optimization studies
- Treatment efficacy evaluation
Investigates diverse therapeutic approaches for chronic ophthalmic conditions requiring long-term management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.